menu
    • menu
    [{"orgOrder":0,"company":"Merck & Co","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"CD24Fc","moa":"","graph1":"Immunology","graph2":"Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Merck & Co \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Merck & Co \/ Not Applicable"},{"orgOrder":0,"company":"TFF Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Tacrolimus","moa":"FK506-binding protein 1A","graph1":"Immunology","graph2":"Phase II","graph3":"TFF Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Inhalation Powder","sponsorNew":"TFF Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"TFF Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"TFF Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Tacrolimus","moa":"FK506-binding protein 1A","graph1":"Immunology","graph2":"Phase I","graph3":"TFF Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Inhalation Powder","sponsorNew":"TFF Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"TFF Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"TFF Pharmaceuticals","sponsor":"Jefferies LLC","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"","productType":"Small molecule","year":"2020","type":"Financing","leadProduct":"Tacrolimus","moa":"FK506-binding protein 1A","graph1":"Immunology","graph2":"Phase I","graph3":"TFF Pharmaceuticals","amount2":0.029999999999999999,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0.029999999999999999,"dosageForm":"Inhalation Powder","sponsorNew":"TFF Pharmaceuticals \/ Jefferies LLC","highestDevelopmentStatusID":"6","companyTruncated":"TFF Pharmaceuticals \/ Jefferies LLC"},{"orgOrder":0,"company":"Aequus Pharmaceuticals","sponsor":"Sandoz B2B","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"","productType":"Small molecule","year":"2020","type":"Agreement","leadProduct":"Tacrolimus","moa":"Calcineurin phosphatase","graph1":"Immunology","graph2":"Approved","graph3":"Aequus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Immediate Release Tablet","sponsorNew":"Aequus Pharmaceuticals \/ Sandoz Canada","highestDevelopmentStatusID":"12","companyTruncated":"Aequus Pharmaceuticals \/ Sandoz Canada"},{"orgOrder":0,"company":"Lipella Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Tacrolimus","moa":"","graph1":"Urology","graph2":"Phase II","graph3":"Lipella Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"","sponsorNew":"Lipella Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Lipella Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"TFF Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Tacrolimus","moa":"FK506-binding protein 1A","graph1":"Immunology","graph2":"Phase I","graph3":"TFF Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Inhalation Powder","sponsorNew":"TFF Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"TFF Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"CTI BioPharma Corp","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Pacritinib","moa":"FLT3","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"CTI BioPharma Corp","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral","sponsorNew":"CTI BioPharma Corp \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"CTI BioPharma Corp \/ Not Applicable"},{"orgOrder":0,"company":"Glenmark Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Tacrolimus","moa":"FK506-binding protein 1A","graph1":"Immunology","graph2":"Approved","graph3":"Glenmark Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Glenmark Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Glenmark Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Marinomed Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Tacrolimus","moa":"FK506 binding protein","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Marinomed Biotech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Eye Drop","sponsorNew":"Marinomed Biotech \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Marinomed Biotech \/ Not Applicable"},{"orgOrder":0,"company":"CTI BioPharma Corp","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Pacritinib","moa":"TYK","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"CTI BioPharma Corp","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral","sponsorNew":"CTI BioPharma Corp \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"CTI BioPharma Corp \/ Not Applicable"},{"orgOrder":0,"company":"Marinomed Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Tacrolimus","moa":"FK506 binding protein","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Marinomed Biotech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Eye Drop","sponsorNew":"Marinomed Biotech \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Marinomed Biotech \/ Not Applicable"},{"orgOrder":0,"company":"Mankind Pharma","sponsor":"Panacea Biotec Limited","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"","productType":"Small molecule","year":"2022","type":"Agreement","leadProduct":"Tacrolimus","moa":"FK506-binding protein 1A","graph1":"Dermatology","graph2":"Approved","graph3":"Mankind Pharma","amount2":0.25,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","amount2New":0.25,"dosageForm":"Capsule","sponsorNew":"Mankind Pharma \/ Panacea Biotec","highestDevelopmentStatusID":"12","companyTruncated":"Mankind Pharma \/ Panacea Biotec"},{"orgOrder":0,"company":"ImmunityBio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","year":"2022","type":"Not Applicable","leadProduct":"Inbakicept","moa":"IL-15","graph1":"Oncology","graph2":"Phase II","graph3":"ImmunityBio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Infusion","sponsorNew":"ImmunityBio \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"ImmunityBio \/ Not Applicable"},{"orgOrder":0,"company":"Lipella Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Tacrolimus","moa":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase II","graph3":"Lipella Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Lipella Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Lipella Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Cook MyoSite","sponsor":"Lipella Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Urology","country":"","productType":"Small molecule","year":"2023","type":"Collaboration","leadProduct":"Tacrolimus","moa":"","graph1":"Urology","graph2":"Phase II","graph3":"Cook MyoSite","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Cook MyoSite \/ Lipella Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"Cook MyoSite \/ Lipella Pharmaceuticals"},{"orgOrder":0,"company":"BNS Ophthalmics","sponsor":"BioNanoSim","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"ISRAEL","productType":"Small molecule","year":"2023","type":"Agreement","leadProduct":"Tacrolimus","moa":"","graph1":"Ophthalmology","graph2":"Preclinical","graph3":"BNS Ophthalmics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"BNS Ophthalmics \/ BioNanoSim","highestDevelopmentStatusID":"4","companyTruncated":"BNS Ophthalmics \/ BioNanoSim"},{"orgOrder":0,"company":"TFF Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Tacrolimus","moa":"","graph1":"Immunology","graph2":"Phase II","graph3":"TFF Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Powder for Inhalation","sponsorNew":"TFF Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"TFF Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"TFF Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Tacrolimus","moa":"","graph1":"Immunology","graph2":"Phase II","graph3":"TFF Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Powder for Inhalation","sponsorNew":"TFF Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"TFF Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Biocon","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Tacrolimus","moa":"","graph1":"Immunology","graph2":"Approved","graph3":"Biocon","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Biocon \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Biocon \/ Not Applicable"},{"orgOrder":0,"company":"TFF Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Tacrolimus","moa":"","graph1":"Immunology","graph2":"Phase II","graph3":"TFF Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"","sponsorNew":"TFF Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"TFF Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"TFF Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Tacrolimus","moa":"","graph1":"Technology","graph2":"Approved","graph3":"TFF Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Technology","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"TFF Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"TFF Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"TFF Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Tacrolimus","moa":"","graph1":"Technology","graph2":"Approved","graph3":"TFF Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Technology","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"TFF Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"TFF Pharmaceuticals \/ Not Applicable"}]

    Find Clinical Drug Pipeline Developments & Deals for Tacrolimus Monohydrate

    Menu

    Tacrolimus Monohydrate

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    DRUG PRODUCT COMPOSITIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    REF. STANDARDS & IMPURITIES

    ANALYTICAL

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            TFF Pharmaceuticals

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed

                            TFF Pharmaceuticals

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Tacrolimus

                            Therapeutic Area : Immunology

                            Study Phase : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            TFF Reports Positive Phase 2 Data for Tacrolimus Powder in Lung Transplant Rejection

                            Details : The company’s lead product candidate TFF TAC (tacrolimus) inhalation powder, is undergoing Phase 2 trial studies for the prevention of lung transplant rejection.

                            Brand Name : TFF TAC

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            August 06, 2024

                            Lead Product(s) : Tacrolimus

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            TFF Pharmaceuticals

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed

                            TFF Pharmaceuticals

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Tacrolimus

                            Therapeutic Area : Immunology

                            Study Phase : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            TFF Pharmaceuticals Provides Update on Tacrolimus Inhalation Powder for Lung Transplant

                            Details : The company’s lead product candidate TFF TAC (tacrolimus) inhalation powder, is undergoing Phase 2 trial studies for the prevention of lung transplant rejection.

                            Brand Name : TFF TAC

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            June 24, 2024

                            Lead Product(s) : Tacrolimus

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            TFF Pharmaceuticals

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed

                            TFF Pharmaceuticals

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Tacrolimus

                            Therapeutic Area : Immunology

                            Study Phase : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            TFF Pharmaceuticals Updates on Tacrolimus Inhalation Powder Phase 2 Trial

                            Details : The company’s lead product candidate TFF TAC (tacrolimus) inhalation powder, is undergoing Phase 2 trial studies for the prevention of lung transplant rejection.

                            Brand Name : TFF TAC

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            May 15, 2024

                            Lead Product(s) : Tacrolimus

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Biocon

                            India arrow
                            Antibody Engineering
                            Not Confirmed

                            Biocon

                            India arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Tacrolimus

                            Therapeutic Area : Immunology

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Biocon Receives Approval for Tacrolimus Capsules from SAHPRA

                            Details : Tacrograf (tacrolimus) is a next-generation, capsule formulation immunosuppressent for the treatment and prevention of prophylaxis of organ rejection after transplant.

                            Brand Name : Tacrograf

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            April 20, 2024

                            Lead Product(s) : Tacrolimus

                            Therapeutic Area : Immunology

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            TFF Pharmaceuticals

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed

                            TFF Pharmaceuticals

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Tacrolimus

                            Therapeutic Area : Immunology

                            Study Phase : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            TFF Pharmaceuticals Presents Interim Data from Phase 2 Study of Tacrolimu

                            Details : TFF TAC (tacrolimus) is a next-generation, direct-to-lung, inhaled dry powder formulation of tacrolimus for the treatment and prevention of prophylaxis of organ rejection in lung transplant.

                            Brand Name : TFF TAC

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            March 25, 2024

                            Lead Product(s) : Tacrolimus

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            TFF Pharmaceuticals

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed

                            TFF Pharmaceuticals

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Tacrolimus

                            Therapeutic Area : Immunology

                            Study Phase : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            TFF Pharmaceuticals Announces Positive Initial Data from Ongoing Phase 2 Trials of TFF VORI and TFF TAC

                            Details : TFF TAC (tacrolimus) is a next-generation, direct-to-lung, inhaled dry powder formulation of tacrolimus for the treatment and prevention of prophylaxis of organ rejection in lung transplant.

                            Brand Name : TFF-TAC

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            December 19, 2023

                            Lead Product(s) : Tacrolimus

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            BNS Ophthalmics

                            Country arrow
                            Antibody Engineering
                            Not Confirmed

                            BNS Ophthalmics

                            Country arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Tacrolimus

                            Therapeutic Area : Ophthalmology

                            Study Phase : Preclinical

                            Sponsor : BioNanoSim

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            BNS and RAFARM Create BNS Ophthalmics to Leverage Nanotechnology in The Development of Novel Ophthalmic Produc...

                            Details : BNSO will develop, manufacture and commercialize a range of innovative ophthalmic pharmaceutical products developed by BioNanoSim, including BNSO-1, a Tacrolimus ocular emulsion developed by its proprietary nano-technology platform to address serious oph...

                            Brand Name : BNSO-1

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            May 30, 2023

                            Lead Product(s) : Tacrolimus

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Preclinical

                            Sponsor : BioNanoSim

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Cook MyoSite

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed

                            Cook MyoSite

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Tacrolimus

                            Therapeutic Area : Urology

                            Study Phase : Phase II

                            Sponsor : Lipella Pharmaceuticals

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Lipella Pharmaceuticals Enters Manufacturing Collaboration Agreement with Cook MyoSite

                            Details : The collaboration aims to facilitate Chemistry, Manufacturing, and Control documentation for Lipella's drug candidate LP-10 (liposomal tacrolimus), aimed at treating hemorrhagic cystitis. LP-10 has been granted Orphan Drug Designation by the FDA.

                            Brand Name : LP-10

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            April 17, 2023

                            Lead Product(s) : Tacrolimus

                            Therapeutic Area : Urology

                            Highest Development Status : Phase II

                            Sponsor : Lipella Pharmaceuticals

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Lipella Pharmaceuticals

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed

                            Lipella Pharmaceuticals

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Tacrolimus

                            Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                            Study Phase : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Lipella Pharmaceuticals Announces Successful Top Line Results of Phase 2A Clinical Trial of LP-10

                            Details : LP-10 is a proprietary liposomal formulation of tacrolimus that is currently being evaluated as a treatment for moderate to severe hemorrhagic cystitis. The product candidate is currently in Phase 2a clinical trial.

                            Brand Name : LP-10

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            January 11, 2023

                            Lead Product(s) : Tacrolimus

                            Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                            Highest Development Status : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            ImmunityBio

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed

                            ImmunityBio

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Inbakicept,Tacrolimus,Mycophenolate Mofetil

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Memory Cytokine-Enhanced Natural Killer Cells Show Promising Results in Leukemia Patients; Data Support Immuni...

                            Details : Study demonstrated that NK cells when stimulated with a cytokine cocktail developed a memory-like phenotype with increased expansion and persistence in vivo, as a treatment for cancer of its m-ceNK platform combined with IL-15 superagonist cytokine fusio...

                            Brand Name : Anktiva

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Not Applicable

                            March 02, 2022

                            Lead Product(s) : Inbakicept,Tacrolimus,Mycophenolate Mofetil

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth